Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association / 임상당뇨병
Journal of Korean Diabetes
;
: 35-40, 2018.
Article
in Korean
| WPRIM
| ID: wpr-726892
ABSTRACT
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Cardiovascular Diseases
/
Weight Loss
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptide 1
/
Glucagon-Like Peptide-1 Receptor
/
Hypoglycemia
/
Hypoglycemic Agents
/
Insulin
/
Obesity
Type of study:
Controlled clinical trial
/
Practice guideline
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS